These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 35133484

  • 1. SUVmax to tumor perimeter distance: a robust radiomics prognostic biomarker in resectable non-small cell lung cancer patients.
    Jiménez Londoño GA, García Vicente AM, Bosque JJ, Amo-Salas M, Pérez-Beteta J, Honguero-Martinez AF, Pérez-García VM, Soriano Castrejón ÁM.
    Eur Radiol; 2022 Jun; 32(6):3889-3902. PubMed ID: 35133484
    [Abstract] [Full Text] [Related]

  • 2. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
    Li C, Tian Y, Shen Y, Wen B, He Y.
    AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
    [Abstract] [Full Text] [Related]

  • 3. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [Abstract] [Full Text] [Related]

  • 4. Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease.
    Lim CH, Hyun SH, Moon SH, Cho YS, Choi JY, Lee KH.
    Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.
    Biomed Mater Eng; 2014 Oct; 24(6):3091-103. PubMed ID: 25227018
    [Abstract] [Full Text] [Related]

  • 6. Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer.
    Domachevsky L, Groshar D, Galili R, Saute M, Bernstine H.
    Eur Radiol; 2015 Nov; 25(11):3361-7. PubMed ID: 25929940
    [Abstract] [Full Text] [Related]

  • 7. Promising Candidate Prognostic Biomarkers in [18F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
    Hovhannisyan-Baghdasarian N, Luporsi M, Captier N, Nioche C, Cuplov V, Woff E, Hegarat N, Livartowski A, Girard N, Buvat I, Orlhac F.
    J Nucl Med; 2024 Apr 01; 65(4):635-642. PubMed ID: 38453361
    [Abstract] [Full Text] [Related]

  • 8. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A, Toschi L, Rossi S, Finocchiaro G, Grizzi F, Mazziotti E, Qehajaj D, Rahal D, Lopci E.
    Clin Lung Cancer; 2020 Jan 01; 21(1):28-36. PubMed ID: 31409523
    [Abstract] [Full Text] [Related]

  • 9. Prognostic importance of 18F-fluorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapy.
    Kanyilmaz G, Benli Yavuz B, Aktan M, Sahin O.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Jan 01; 39(1):20-26. PubMed ID: 31668790
    [Abstract] [Full Text] [Related]

  • 10. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
    Im HJ, Oo S, Jung W, Jang JY, Kim SW, Cheon GJ, Kang KW, Chung JK, Kim EE, Lee DS.
    Medicine (Baltimore); 2016 May 01; 95(19):e3686. PubMed ID: 27175707
    [Abstract] [Full Text] [Related]

  • 11. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K, Okita R, Saisho S, Yukawa T, Maeda A, Nojima Y, Nakata M.
    Ann Nucl Med; 2015 Dec 01; 29(10):854-60. PubMed ID: 26254228
    [Abstract] [Full Text] [Related]

  • 12. A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [18F]FDG PET/CT metabolic parameters, inflammatory markers, and clinical variables.
    Zhang L, Xu C, Zhang X, Wang J, Jiang H, Chen J, Zhang H.
    Eur Radiol; 2023 Mar 01; 33(3):1757-1768. PubMed ID: 36222865
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 01; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 14. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y, Suzuki K, Takamochi K, Matsunaga T, Oh S.
    Eur J Cardiothorac Surg; 2013 Jul 01; 44(1):83-7. PubMed ID: 23233074
    [Abstract] [Full Text] [Related]

  • 15. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer.
    Song BI, Kim HW, Won KS, Ryu SW, Sohn SS, Kang YN.
    Medicine (Baltimore); 2015 Jul 01; 94(26):e1037. PubMed ID: 26131811
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.
    Eur J Nucl Med Mol Imaging; 2012 Jan 01; 39(1):27-38. PubMed ID: 21946983
    [Abstract] [Full Text] [Related]

  • 17. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V, Matano E, De Placido S, Del Vecchio S.
    Ann Nucl Med; 2019 Dec 01; 33(12):937-944. PubMed ID: 31612416
    [Abstract] [Full Text] [Related]

  • 18. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
    Yan H, Wang R, Zhao F, Zhu K, Jiang S, Zhao W, Feng R.
    Acta Radiol; 2011 Jul 01; 52(6):646-50. PubMed ID: 21508201
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer.
    Park HL, Boo SH, Park SY, Moon SW, Yoo IR.
    Eur Radiol; 2023 Oct 01; 33(10):7274-7283. PubMed ID: 37060445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.